Chardan downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company will be discontinuing the Phase II FIRCE-1 clinical trial of its lead autologous CD22 CAR-T candidate firi-cel after an ad hoc analysis prompted by recent safety events found an unfavorable benefit/risk profile, the analyst tells investors in a research note. The firm moved to the sidelines pending visibility on CRG-023 data timelines and details on the company’s allogeneic strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRGX: